Gilead ties up with Tentarix for cancer, inflammatory disease therapies
Send a link to a friend
[August 16, 2023]
(Reuters) -Gilead Sciences said on Tuesday it had entered into an
agreement with privately held Tentarix Biotherapeutics to develop
therapies for cancer and inflammatory diseases.
Tentarix will receive upfront payments and an equity investment totaling
$66 million from Gilead, which has the option to buy up to three of the
drug developer's units for $80 million each, the companies said.
The deal gives Gilead access to Tentarix's proprietary drug development
platform for antibody-based therapies that specifically target immune
cells related to the disease without activating other immune cells that
may lead to adverse events.
![](http://archives.lincolndailynews.com/2023/Aug/16/images/ads/current/sunag_sda_FAIR_2023.png)
[to top of second column]
|
![](../images/081623PIX/health45.jpg)
The logo of Gilead Sciences Inc
pharmaceutical company is seen in Oceanside, California, U.S., April
29, 2020. REUTERS/Mike Blake/File Photo
![](http://archives.lincolndailynews.com/2023/Aug/16/images/ads/current/debbiesflora_lda_081123.png) Gilead earlier this month flagged a
more than 25% jump in research and development costs owing to
multi-year plans it undertook to diversify its pipeline to expand
beyond HIV drugs, its strongest revenue driver.
(Reporting by Mariam Sunny in Bengaluru; Editing by Arun Koyyur and
Shounak Dasgupta)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |